Physician profile
Augustine O Eleje
NPI 1902843030
$37,458.07
in general payments reported to CMS, 2019-2025
63 companies · $4,440 in 2025
The $4,440 reported for 2025 was more than what 99% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,332 · 2020: $4,556 · 2021: $5,998 · 2022: $5,693 · 2023: $4,893 · 2024: $4,546 · 2025: $4,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,774.02 |
| Education | $105.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,141.71 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $3,109.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $3,070.22 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,607.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,336.04 | 2019-2025 | |
| Lilly USA, LLC | $2,239.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $2,062.64 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,797.50 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,382.29 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $1,288.18 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,242.75 | 2019-2024 | Xarelto, Spravato |
| Allergan, INC. | $1,070.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $836.29 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $835.13 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $775.54 | 2019-2025 | Xifaxan |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Eleje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.